| P50 | author | Teresa Garcí-Berrocoso | Q82805551 |
| | Joan Montaner | Q60879344 |
| | Laura Ramiro | Q61154399 |
| P2093 | author name string | Alba Simats | |
| P2860 | cites work | Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome | Q24794415 |
| | Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat | Q28189196 |
| | Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 |
| | Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke | Q29619330 |
| | IL-4 in the brain: a cytokine to remember | Q30416623 |
| | Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study | Q31028414 |
| | Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats | Q31797874 |
| | Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats | Q31797891 |
| | Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain | Q32051264 |
| | Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production | Q33276036 |
| | Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone | Q33392391 |
| | Functional status of peripheral blood T-cells in ischemic stroke patients | Q33525563 |
| | Interleukin-6 and soluble intercellular adhesion molecule-1 in acute brain ischaemia | Q80802078 |
| | Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project | Q81105578 |
| | Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke | Q83483859 |
| | SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial | Q88137912 |
| | Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke | Q95784438 |
| | Increased cytokine release from peripheral blood cells after acute stroke. | Q48118212 |
| | Novel diagnostic test for acute stroke | Q48118544 |
| | Clinical severity of ischemic stroke and neural damage biomarkers in the acute setting: the STROke MArkers (STROMA) study. | Q48118597 |
| | Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. | Q48121709 |
| | Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke | Q48130992 |
| | Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke | Q48138737 |
| | Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease | Q48149523 |
| | Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene | Q48151099 |
| | Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. | Q48179242 |
| | Early Biomarkers of Stroke | Q48193653 |
| | Anti-P-selectin antibody attenuates rat brain ischemic injury | Q48211836 |
| | Neuroprotective effects of TGF-beta 1. | Q48227756 |
| | Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes | Q48231105 |
| | Link between interleukin-10 level and outcome after ischemic stroke | Q48283403 |
| | Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke | Q48303546 |
| | Increase in Plasma Matrix Metalloproteinase-9 in Acute Stroke Patients With Thrombolysis Failure | Q48308339 |
| | P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. | Q48311717 |
| | Protective effect of anti-intercellular adhesion molecule-1 antibody on global cerebral ischemia/reperfusion injury in the rat. | Q48332261 |
| | New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. | Q48342084 |
| | TNF-alpha: a risk factor for ischemic stroke | Q48368449 |
| | Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke | Q48371010 |
| | Levels of vascular cell adhesion molecule-1 and endothelin-1 in ischemic stroke: a longitudinal prospective study. | Q48373327 |
| | IL-10 reduces rat brain injury following focal stroke | Q48401527 |
| | Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke | Q48458187 |
| | Multiple atherosclerosis-related biomarkers associated with short- and long-term mortality after stroke | Q48462385 |
| | Soluble or soluble/membrane TNF-α inhibitors protect the brain from focal ischemic injury in rats. | Q48473077 |
| | Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site | Q48479997 |
| | Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia | Q48524719 |
| | Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. | Q48527561 |
| | Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. | Q48532402 |
| | Neuroprotective effects of TNF binding protein in focal cerebral ischemia | Q48539461 |
| | Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression | Q48599588 |
| | Inflammatory mediators and stroke: new opportunities for novel therapeutics | Q33718239 |
| | Imbalance between IL-17A-producing cells and regulatory T cells during ischemic stroke. | Q33759877 |
| | Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. | Q33865619 |
| | Therapeutically targeting neuroinflammation and microglia after acute ischemic stroke. | Q33893264 |
| | Biochemical and inflammatory biomarkers in ischemic stroke: translational study between humans and two experimental rat models. | Q34042609 |
| | Role of IL-1alpha and IL-1beta in ischemic brain damage. | Q34084693 |
| | Tumor necrosis factor signaling. | Q34185821 |
| | The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection | Q34320047 |
| | Potential of anticytokine therapies in central nervous system ischaemia | Q34452055 |
| | Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis | Q34471200 |
| | Adhesion molecules of immunoglobulin gene superfamily in stroke. | Q34571500 |
| | Cytokines, inflammation, and pain | Q34618022 |
| | Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume | Q34729372 |
| | DAMP signaling is a key pathway inducing immune modulation after brain injury. | Q34946249 |
| | Mechanisms, challenges and opportunities in stroke | Q35120144 |
| | Role of cell adhesion molecules in acute ischemic stroke | Q35165797 |
| | A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients | Q35484320 |
| | Acute phase IL-10 plasma concentration associates with the high risk sources of cardiogenic stroke | Q35553390 |
| | Functional role of regulatory lymphocytes in stroke: facts and controversies | Q35554595 |
| | Neuronal Interleukin-4 as a Modulator of Microglial Pathways and Ischemic Brain Damage | Q35941396 |
| | Essential role of interleukin-6 in post-stroke angiogenesis | Q35986676 |
| | Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats | Q36211358 |
| | E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases | Q36252961 |
| | Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. | Q36405496 |
| | Severe stroke induces long-lasting alterations of high-mobility group box 1. | Q36489511 |
| | Interleukin-4 Is Essential for Microglia/Macrophage M2 Polarization and Long-Term Recovery After Cerebral Ischemia | Q36510329 |
| | Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction | Q36790556 |
| | RIGOR guidelines: escalating STAIR and STEPS for effective translational research | Q36816551 |
| | Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke | Q36880908 |
| | Annexin A1 in the brain--undiscovered roles? | Q37080600 |
| | Plasma level of IL-6 and its relationship to procoagulant and fibrinolytic markers in acute ischemic stroke | Q37205257 |
| | Bioenergetics of cerebral ischemia: a cellular perspective | Q37221302 |
| | Molecular and Cellular Responses to Interleukin-4 Treatment in a Rat Model of Transient Ischemia | Q37350621 |
| | Prolonged elevation of cytokine levels after human acute ischaemic stroke with evidence of individual variability | Q48611652 |
| | Intracerebral interleukin-10 injection modulates post-ischemic neuroinflammation: an experimental microarray study | Q48661514 |
| | Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. | Q48687973 |
| | Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke | Q48691904 |
| | Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. | Q48720131 |
| | Nerve growth factor and transforming growth factor-beta serum levels in acute stroke patients. Possible involvement of neurotrophins in cerebrovascular disease | Q48738455 |
| | Use of biomarkers in triage of patients with suspected stroke | Q48745218 |
| | Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome | Q48782589 |
| | Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct | Q48828248 |
| | A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke | Q48860420 |
| | Interleukin-1 in Stroke: From Bench to Bedside | Q48868201 |
| | Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. | Q48887459 |
| | IL-6: an early marker for outcome in acute ischemic stroke | Q48899503 |
| | Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome | Q48921136 |
| | Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. | Q48936696 |
| | Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke | Q48937093 |
| | Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia | Q49021460 |
| | Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. | Q49044940 |
| | Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils | Q49120991 |
| | Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association | Q49546493 |
| | Interleukin-10 may protect against progressing injury during the acute phase of ischemic stroke. | Q50736479 |
| | Beneficial potential of intravenously administered IL-6 in improving outcome after murine experimental stroke. | Q50956384 |
| | IL-1β, TNF-α, and IL-6 levels in gingival fluid and serum of patients with ischemic stroke. | Q51234135 |
| | True Effects or Bias? MMP-2 and MMP-9 Serum Concentrations after Acute Stroke. | Q51693689 |
| | Blocking of α4 integrin does not protect from acute ischemic stroke in mice. | Q51740914 |
| | Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. | Q53741816 |
| | Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. | Q53901664 |
| | Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. | Q53984833 |
| | A Transforming Growth Factor-β Antagonist Unmasks the Neuroprotective Role of This Endogenous Cytokine in Excitotoxic and Ischemic Brain Injury | Q60597724 |
| | Matrix Metalloproteinase Expression After Human Cardioembolic Stroke | Q60669995 |
| | Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. | Q64907051 |
| | Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke | Q71704289 |
| | Anti–Intercellular Adhesion Molecule–1 Antibody Reduces Ischemic Cell Damage After Transient But Not Permanent Middle Cerebral Artery Occlusion in the Wistar Rat | Q71948073 |
| | Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats | Q72139375 |
| | Circulating intercellular adhesion molecule-1 levels and neutrophil adhesion in stroke | Q72219324 |
| | Interleukin-6 and interleukin-1 receptor antagonist in acute stroke | Q72307215 |
| | Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat | Q72406787 |
| | Proinflammatory cytokines and early neurological worsening in ischemic stroke | Q73048866 |
| | Inhibition of tumor necrosis factor and amelioration of brain infarction in mice | Q73089295 |
| | Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke | Q73271832 |
| | Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients | Q75437705 |
| | Endothelial markers and adhesion molecules in acute ischemic stroke--sequential change and differences in stroke subtype | Q77738035 |
| | Elevated soluble intercellular adhesion molecule-1 levels are associated with poor short-term prognosis in middle-aged patients with acute ischaemic stroke | Q80483754 |
| | Inflammatory mechanisms in ischemic stroke: therapeutic approaches | Q37634142 |
| | Discriminative capacity of biomarkers for acute stroke in the emergency department | Q37736759 |
| | Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? | Q37800999 |
| | Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review | Q37806387 |
| | Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies | Q37919706 |
| | Post-stroke immunodeficiency: effects of sensitization and tolerization to brain antigens | Q38053493 |
| | Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. | Q38236852 |
| | Post-ischemic inflammation regulates neural damage and protection | Q38263497 |
| | Mechanical Thrombectomy in and Outside the REVASCAT Trial: Insights From a Concurrent Population-Based Stroke Registry | Q38401318 |
| | Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage | Q38525908 |
| | Neuroinflammatory biomarkers: From stroke diagnosis and prognosis to therapy | Q38622488 |
| | Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke | Q38659368 |
| | Characterization of secretomes from a human blood brain barrier endothelial cells in-vitro model after ischemia by stable isotope labeling with aminoacids in cell culture (SILAC). | Q38807780 |
| | Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. | Q38931129 |
| | Postischemic Inflammation in Acute Stroke | Q39082314 |
| | Reparative effects of interleukin-1 receptor antagonist in young and aged/co-morbid rodents after cerebral ischemia | Q39179831 |
| | The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome | Q39871785 |
| | Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. | Q40336067 |
| | Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia | Q40561922 |
| | Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies | Q40569474 |
| | Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial | Q40594401 |
| | Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. | Q40607050 |
| | Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain | Q40746247 |
| | Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke | Q40754122 |
| | Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat. | Q40814212 |
| | Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia | Q40878286 |
| | Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke | Q41314097 |
| | Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia. | Q41511386 |
| | Transforming growth factor-betas in neurodegenerative disease | Q41699811 |
| | Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. | Q42015872 |
| | Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. | Q43263221 |
| | Acute-phase reactants and cytokines in ischemic stroke: do they have any relationship with short-term mortality? | Q43725126 |
| | Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target | Q43948946 |
| | An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis | Q44865641 |
| | Inflammatory biomarkers in blood of patients with acute brain ischemia | Q44894573 |
| | Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients | Q45210045 |
| | Plasma biomarkers in the diagnosis of acute ischemic stroke | Q45330979 |
| | Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia | Q45881278 |
| | A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. | Q45982189 |
| | Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficit. | Q46010596 |
| | Evaluation of the inflammatory response in sera from acute ischemic stroke patients by measurement of IL-2 and IL-10. | Q46064621 |
| | Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. | Q46227152 |
| | Plasma Glial Fibrillary Acidic Protein, Copeptin, and Matrix Metalloproteinase-9 Concentrations among West African Stroke Subjects Compared with Stroke-Free Controls | Q46982479 |
| | Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. | Q47349753 |
| | Different cytokine levels in thrombolysis patients as predictors for clinical outcome | Q47409673 |
| | Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. | Q47432077 |
| | Inhibition of interleukin-6 abolishes the promoting effects of pair housing on post-stroke neurogenesis | Q47657690 |
| | Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke | Q47730652 |
| | Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats | Q48106802 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| | pharmacology | Q128406 |
| P304 | page(s) | 1756286418789340 | |
| P577 | publication date | 2018-08-06 | |
| P1433 | published in | Therapeutic advances in neurological disorders | Q26842039 |
| P1476 | title | Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management | |
| P478 | volume | 11 | |